Tides Express | Sirius Therapeutics to Present Phase I Clinical Data and Product Profile of siRNA Drug SRSD107

December 20243DayShanghai, China and San Diego, USA: Sirius Therapeutics (SHANGHAI) Co., Ltd. ("Sirius Therapeutics") announced that preliminary data from the Phase I clinical trial of its next-generation FXI-siRNA long-acting anticoagulant drug SRSD107 will be presented in a poster session at the 66th American Society of Hematology Annual Meeting. The meeting will be held from December 7 to 10, 2024, at the San Diego Convention Center and online.

Dr. Peichuan Yu, Chief Medical Officer of Sirius Therapeutics, stated: "SRSD107 is a transformative small nucleic acid drug for the prevention and treatment of thromboembolic diseases. The data to be presented at ASH 2024 demonstrates that SRSD107 not only exhibits good safety and efficacy but also offers the convenience of dosing once every six months or once a year, making it highly suitable for patients requiring long-term anticoagulation therapy. Current epidemiological and genetic evidence supports the feasibility of targeting FXI as an anticoagulant strategy. SRSD107 prevents thrombotic events by inhibiting FXI expression without increasing the risk of bleeding. We will actively advance its Phase II clinical trials in the future."

Thrombosis is a blood clot that restricts blood flow within blood vessels and can occur in either arterial or venous circulation. It serves as the common pathological basis for most myocardial infarctions, ischemic strokes, and venous thromboembolism (VTE). Globally, one in four people die from diseases caused by thromboembolism.

AboutSRSD107 Injection

SRSD107 Injection is a double-stranded small interfering RNA (siRNA) drug independently developed by Sirius Therapeutics. By specifically targeting the liver-directed human coagulation factor XI (FXI) mRNA, it inhibits the protein expression of FXI, blocking the activation of the intrinsic coagulation pathway, thereby exerting an anticoagulant effect. Preclinical trial data show that a single subcutaneous injection of SRSD107 can reduce the concentration of FXI in peripheral blood by nearly 100%, with effects lasting up to half a year without any bleeding observed. With its potent, long-lasting efficacy and favorable safety profile, SRSD107 has the potential to become a first-in-class and best-in-class next-generation safer anticoagulant.Anticoagulant drugs.

AboutSirius Therapeutics

Sirius Therapeutics is an innovative biotechnology company dedicated to the mission of advancing human health and well-being. Focusing on the development of next-generation nucleic acid therapies in the field of cardiovascular diseases, the company aims to become a leader in revolutionizing the prevention and treatment of chronic diseases. Established in 2021, it was incubated by an internationally outstanding management team and globally renowned healthcare investment institutions. The company adopts an international strategic positioning, leveraging the talent and resource advantages of both the United States and China in the field of small nucleic acid therapies. It has established a layout with the U.S. as the source of innovative discovery and China as the global translational medicine hub. Utilizing its core technology platform for small nucleic acid drug research and development, Sirius Therapeutics has developed a diversified product pipeline with multiple programs possessing first-in-class or best-in-class potential, showcasing a competitive edge on a global scale.